Cardiovascular disease is the leading cause of death for women in North America, and women with heart failure often...
Cardiac Resynchronization Therapy Devices (CRT)
Cardiac Resynchronization Therapy Devices (CRT) are cardiac electrophysiology (EP) systems that include a small electronic device that is surgically implanted into a pocket of skin to help both ventricles contract together. They are also called biventricular pacemakers. These systems can be used for pacing only, or can include a built-in defibrillator.
-
-
The U.S. Food and Drug Administration (FDA) approved the Barostim Neo System for the improvement of symptoms in patients with advanced heart failure who are not suited for treatment with other...
-
MRI-compatible ICDs is a growing trend in the market. This example is Biotronik's Lumas 740 ICD.
This is a brief overview of updates on implantable cardioverter defibrillators (ICD), ...
-
May 15, 2019 — A new infection risk scoring system has been developed based on data from the large PADIT Trial.[1] The new scoring system was presented as a follow up to that study during a late-...
News | EP Lab | September 08, 2020
September 8, 2020 - A new study presented at the 2020 European Society of Cardiology (ESC) Congress shows that...
News | EP Lab | July 13, 2020
July 13, 2020 - The U.S. Food and Drug Administration (FDA) has approved Abbott's next-generation Gallant implantable...
Left bundle branch (LBBP) activation imaging shown using wall motion color codes on dyamic echo imaging from Canon.
News | Cardiac Resynchronization Therapy Devices (CRT) | May 13, 2020
May 13, 2020 — Cardiac resynchronization therapy (CRT) using biventricular pacing (BVP) or His bundle pacing (HBP) is...
Valentina Kutyifa, M.D., Ph.D., University of Rochester Medical Center, Rochester, N.Y., is doing research in the BIO-LIBRA Study to determine it ICD or CRT-D devices work better in men or women with heart failure often present with non-ischemic cardiomyopathy.
Feature | Cardiac Resynchronization Therapy Devices (CRT) | March 09, 2020 | Valentina Kutyifa M.D., Ph.D.
Cardiovascular disease is the leading cause of death for women in North America, and women with heart failure often...
Earlier this year, Medtronic began a worldwide pivotal study evaluating its investigational Extravascular Implantable Cardioverter Defibrillator (EV ICD) system to treat dangerously fast heart rhythms. The EV ICD system is designed to deliver lifesaving defibrillation and pacing therapy via a device the same size as traditional, transvenous ICDs, but with a lead (thin wire) placed outside the heart and veins.
Feature | EP Lab | November 11, 2019 | Hrishikesh Kadam
Cardiac rhythm management (CRM) devices in use today are evolving to raise the bar beyond monitoring and managing...
Similar to a pacemaker, the Barostim Neo System uses a pulse generator implanted below the collar bone with a lead that attaches to the carotid artery in the neck. It delivers electrical impulses to baroreceptors in the neck, which sense how blood is flowing through the carotid arteries and relays information to the brain. The brain, in turn, sends signals to the heart and blood vessels that relax the blood vessels and inhibit the production of stress-related hormones to reduce heart failure symptoms.
Technology | Heart Failure | August 19, 2019
August 19, 2019 — The U.S. Food and Drug Administration (FDA) granted market clearance the Barostim Neo System for the...
A physician explaining an implantable cardioverter defibrillator (ICD) to a patient. Image courtesy of Biotronik.
Feature | Implantable Cardioverter Defibrillator (ICD) | May 24, 2019 | Dave Fornell, Editor
This is a brief overview of updates on implantable cardioverter defibrillators (ICD), including new technology...
Feature | HRS | May 15, 2019 | Dave Fornell, Editor
May 15, 2019 — The Heart Rhythm Society (HRS) had 21 late-breaking study presentations at the 2019 Heart Rhythm...
![A new infection risk scoring system has been developed based on data from the large PADIT Trial.[1] The new scoring system was presented as a follow up to that study during a late-breaking session at Heart Rhythm 2019, the Heart Rhythm Society's 40th Annual Scientific Sessions.](https://www.dicardiology.com/sites/default/files/styles/content_feed_medium/public/PADIT_Infection_Risk_score.jpg?itok=Lw5DFj5l)
Figure 1: The PADIT infection risk score ranging from 0 to 14 points classified patients into three risk groups, low (0-4), intermediate (5-6) and high (≥7). The risk groups had rates of hospitalization for infection of 0.51%, 1.42% and 3.41%, respectively
News | EP Lab | May 15, 2019
May 15, 2019 — A new infection risk scoring system has been developed based on data from the large PADIT Trial.[1] The...
News | EP Lab | May 15, 2019
May 15, 2019 - Three new studies show that patients who are medically indicated for implantable heart devices,...
News | Cardiac Resynchronization Therapy Devices (CRT) | May 15, 2019 | Dave Fornell, Editor
May 15, 2019 — A pilot trial has shown His pacing in cardiac resynchronization therapy (CRT) has been shown to...
News | EP Lab | May 13, 2019
May 13, 2019 – Results from a new survey are the first to report a large discrepancy in patient’s knowledge of their...
News | Pacemakers | May 07, 2019 | Dave Fornell, Editor
May 7, 2019 — The U.S. Food and Drug Administration (FDA) issued a safety communication to alert healthcare providers...
News | Cardiac Resynchronization Therapy Devices (CRT) | April 29, 2019
April 29, 2019 — Biotronik announced the full commercial launch of the Acticor device family, including Acticor DX and...
News | Cardiac Resynchronization Therapy Devices (CRT) | April 18, 2019
April 18, 2019 – Biotronik announced the European market release of what it calls the world’s smallest implantable...
